You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

127 Results
Regimen
Intent: Adjuvant
Oct 2017
Regimen
Regimen
Intent: Palliative, Adjuvant
Nov 2017
Regimen
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative, Adjuvant
Sep 2017
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Adjuvant
Nov 2017
Regimen
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Adjuvant
Nov 2017
Regimen
Cancer Type:
Sarcoma, 
Osteogenic / Bone, 
Soft Tissue
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Soft Tissue, 
Uterine
Intent: Palliative, Adjuvant
Dec 2017
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Exceptional Access Program
    lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
Exceptional Access Program
    lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
Jul 2025

Pages